Yarrow Bioscience (NASDAQ:YARW) Sees Significant Increase in Short Interest

Key Points

• Short interest more than doubled to 126,528 shares as of September 15, up 123.9% from August 31; approximately 4.9% of shares are sold short.
• Shares opened at $25.54, well below the 52-week high of $46.95. The company reported a quarterly loss of $3.51 per share, missing estimates by $3.33, while revenue of $0.10 million fell short of expectations.
• Analysts give the stock an overall “Hold” rating with a $58 consensus price target, while institutional investors own 83.78% of the company’s shares.

Yarrow Bioscience (NASDAQ:YARW - Get Free Report) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 126,528 shares, an increase of 123.9% from the August 31st total of 56,499 shares. Approximately 4.9% of the shares of the stock are sold short. Based on an average trading volume of 170,937 shares, the short-interest ratio is presently 0.7 days.

Yarrow Bioscience Stock Down 2.0%

Shares of NASDAQ:YARW opened at $25.54 on Friday. Yarrow Bioscience has a 52 week low of $16.00 and a 52 week high of $46.95. The stock has a market cap of $68.19 million, a PE ratio of -1.74 and a beta of 2.01. The business has a fifty day simple moving average of $34.10.

Yarrow Bioscience (NASDAQ:YARW - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33). Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%. The business had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.20 million.

Yarrow Bioscience Announces Dividend

The business also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were given a dividend of $19.00 per share.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wall Street Zen raised Yarrow Bioscience to a "hold" rating in a research note on Saturday, August 22nd. TD Cowen initiated coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They issued a "buy" rating on the stock. Finally, BTIG Research began coverage on Yarrow Bioscience in a report on Monday, August 3rd. They set a "buy" rating and a $58.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $58.00.

Hedge Funds Weigh In On Yarrow Bioscience

Institutional investors and hedge funds have recently modified their holdings of the stock. Nantahala Capital Management LLC bought a new position in shares of Yarrow Bioscience during the 2nd quarter valued at approximately $1,301,400,000. ADAR1 Capital Management LLC bought a new stake in Yarrow Bioscience in the second quarter worth $1,920,000. Braidwell LP purchased a new position in Yarrow Bioscience during the second quarter worth $596,000. T3 Companies LLC purchased a new position in Yarrow Bioscience during the fourth quarter worth $548,000. Finally, Susquehanna International Group LLP purchased a new position in Yarrow Bioscience during the second quarter worth $77,000. Hedge funds and other institutional investors own 83.78% of the company's stock.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.